Alexza Pharmaceuticals Oct 11th FDA Decision for Staccato Technology

Image via Wikipedia Time to start buying more shares of Alexza Pharmaceuticals (ALXA). Another promising run-up play for October is Alexza Pharmaceuticals and its lead candidate AZ-004, which is an inhalation product candidate for the rapid treatment of agitation in patients with schizophrenia or bi-polar disorder. It has a PDUFA(FDA Decision) date of October 11th, 2010.

Biovail, Valeant Pharmaceuticals, GSK gain FDA recommendation for Epilepsy drug Potiga

Image via Wikipedia

Today saw some good news from the FDA as they recommended the joint venture drug, Potiga, by Valeant Pharmaceuticals and Glaxo SmithKline. Valeant is in merger acquisitions with Biovail that should be completed by the year's end.

U.S. Food and Drug Administration advisory committee voted unanimously 11-0 that clinical studies had provided substantial evidence on the safety and effectiveness of ezogabine to treat epilepsy. The Prescription Drug User Fee Act goal date for the FDA to complete its review of the drug’s application is August 30. The drug will be aimed at patients whose other epilepsy medications failed.

Market Thoughts for Wednesday August 11th

The market took a hammering today but some stocks actually performed or are now great buys. The DOW Industrial average DIJA is closing sharply lower today at 10379. That's a 265 drop from yesterdays close of 10644 and a 2.49% decline as Global Fear strikes domestic and foreign markets.

Today's top performers in BioPharma for August 11th.

Biotech